Merck To Spin Out A New Company, Following Industry's Downsizing Trend

Merck will spinout its mature franchises, including women's health products, into a new company that will have about $6bn-$6.5bn in 2021 revenues and be poised for modest growth.

SC2002_Notebook_385032373_1200.jpg
Merck is spinning out women's health and legacy brands and getting smaller

Big pharma is getting smaller and more focused, not bigger, and now Merck & Co. Inc. is the latest company to announce that it will spin out its more mature pharmaceutical products. Merck announced on 5 February that it will spin off its women's health, legacy brands and biosimilars into a new publicly traded company.

Merck will remain focused on its high-growth drivers: oncology – namely the PD-1 inhibitor Keytruda (pembrolizumab), vaccines, hospital and animal...

More from Strategy

More from Business